PART I In this Annual Report, unless the context requires otherwise, references to the Company, Alzamend, we, our company and us refer to Alzamend Neuro, Inc., a Delaware corporation and its subsidiary. Company Overview We are a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). With our two product candidates, we aim t...
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-07-22 | 2025-04-30 | 0001214659-25-010763 | EDGAR | 80K words |
| 2024-07-30 | 2024-04-30 | 0001214659-24-013191 | EDGAR | — |
| 2023-07-27 | 2023-04-30 | 0001214659-23-010076 | EDGAR | — |
| 2022-07-19 | 2022-04-30 | 0001214659-22-008985 | EDGAR | — |
| 2021-07-29 | 2021-04-30 | 0001214659-21-007963 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-11 | 2026-01-31 | 0001214659-26-003166 | EDGAR | 21K words |
| 2025-12-09 | 2025-10-31 | 0001214659-25-017793 | EDGAR | — |
| 2025-09-10 | 2025-07-31 | 0001214659-25-013609 | EDGAR | — |
| 2025-03-10 | 2025-01-31 | 0001214659-25-004123 | EDGAR | — |
| 2024-12-11 | 2024-10-31 | 0001214659-24-020264 | EDGAR | — |
| 2024-09-11 | 2024-07-31 | 0001214659-24-016346 | EDGAR | — |
| 2024-03-25 | 2024-01-31 | 0001214659-24-005088 | EDGAR | — |
| 2023-12-15 | 2023-10-31 | 0001214659-23-016500 | EDGAR | — |
| 2023-09-13 | 2023-07-31 | 0001214659-23-012326 | EDGAR | — |
| 2023-03-15 | 2023-01-31 | 0001214659-23-003850 | EDGAR | — |
| 2022-12-12 | 2022-10-31 | 0001214659-22-014779 | EDGAR | — |
| 2022-09-13 | 2022-07-31 | 0001214659-22-011092 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-20 | 0001214659-26-003620 | EDGAR | 1K words |
| 2026-03-06 | 0001214659-26-002932 | EDGAR | — |
| 2025-11-18 | 0001214659-25-016885 | EDGAR | — |
| 2025-10-14 | 0001214659-25-014950 | EDGAR | — |
| 2025-10-09 | 0001214659-25-014818 | EDGAR | — |
| 2025-09-25 | 0001214659-25-014200 | EDGAR | — |
| 2025-08-01 | 0001214659-25-011357 | EDGAR | — |
| 2025-07-23 | 0001214659-25-010830 | EDGAR | — |
| 2025-07-09 | 0001214659-25-010209 | EDGAR | — |
| 2025-05-08 | 0001214659-25-007204 | EDGAR | — |
109 total filings indexed. 82 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001677077 |
| Ticker | ALZN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.alzamend.com |
| Listed | 2021-06-15 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report